Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GSK’s X-Factor: Augmentin XR, Other Line Extensions Key To Growth

Oct 28 2002

• By The Pink Sheet

Related Content

SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate

Nov 06 2000

GSK Flovent/Advair Diskus Needs More COPD Data; Serevent Cleared For COPD

Apr 01 2002

GSK Augmentin XR Will Be Available In Mid-October, Priced At $9 Per Day

Sep 30 2002

Augmentin ES-600 Label Places Limit On Use For Penicillin-Resistant Strains

Jul 02 2001

Bristol Metaglip Launch Set For November; Third Metformin Line-Extension

Oct 28 2002

Generic Prilosec Launch Awaits Negotiations Between Andrx And Schwarz

Oct 21 2002

Naprelan Generic Exclusivity Settled; Andrx Sees Three Near-Term Launches

Jul 15 2002

GSK Avandamet Antidiabetic Combo Expected In Pharmacies In November

Oct 14 2002

Geneva Generic Augmentin Distribution Limited To Warehousing Drug Chains

Aug 19 2002

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window